Compared to the MMR wild-type cases, the tumor mutation burden (TMB) in MMR-mutant cases was significantly higher (84.9 ± 13.0 vs. 15.1 ± 0.9; P < .0001) (Supplementary Figure 1), and these patients had shorter overall survival (median survival 78.5 months vs. 161 months; Hazard ratio (HR): 3.7 (1.4–10.0); P = .0069) but not recurrence/progression-free survival intervals, although there was a trend toward shorter recurrence-free interval in the MMR-mutant cases (P = .0528) (Figure 3). This evidence concerns the gene MRC1 and neoplasm.